A new study provides more evidence that GLP-1 RAs don’t raise the risk for pancreatic cancer and may in fact offer some protection.

In any case, the present analysis was still limited by the lack of accounting for variables such as the different types and doses of GLP-1 agonists used, the difference between a surgery versus ...

A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, ...

Of those, 4,052 were prescribed a GLP-1 receptor agonist. Compared with controls, those prescribed medication were slightly older (mean 15.5 years vs 14.7 years), more often female, had higher body ...